• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PAROXETINE Drug Record

  • Summary
  • Interactions
  • Claims
  • PAROXETINE chembl:CHEMBL490 Approved

    Alternate Names:

    PEXEVA
    PAXIL
    BRL-29060
    PAROXETINE
    PAXIL [AS HYDROCHLORIDE]
    (−)-(3S,4R)-4-(P-FLUOROPHENYL)-3-((3,4-(METHYLENEDIOXY)PHENOXY)METHYL)PIPERIDINE
    (3S-TRANS)-3-((1,3-BENZODIOXOL-5-YLOXY)METHYL)-4-(4-FLUOROPHENYL)PIPERIDINE
    PAROXETINUM
    (-)-(3S,4R)-4-(P-FLUOROPHENYL)-3-((3,4-(METHYLENEDIOXY)PHENOXY)METHYL)PIPERIDINE
    PAROXETINA
    pubchem.compound:43815
    chembl:CHEMBL490
    drugbank:00715
    chemidplus:61869-08-7
    rxcui:32937

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antidepressant
    Drug Class antidepressive agents, second-generation
    Year of Approval 1992
    Drug Categories agents producing tachycardia
    Drug Categories anticholinergic agents
    Drug Categories central nervous system depressants
    Drug Categories cytochrome p-450 cyp1a2 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp1a2 substrates
    Drug Categories cytochrome p-450 cyp2b6 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp2c19 inhibitors
    Drug Categories cytochrome p-450 cyp2c19 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp2c19 substrates
    Drug Categories cytochrome p-450 cyp2c9 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp3a inhibitors
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cytochrome p-450 cyp3a4 inhibitors
    Drug Categories cytochrome p-450 cyp3a4 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp3a4 substrates
    Drug Categories cytochrome p-450 substrates
    Drug Categories drugs causing inadvertant photosensitivity
    Drug Categories hypoglycemia-associated agents
    Drug Categories muscarinic antagonists
    Drug Categories p-glycoprotein inhibitors
    Drug Categories photosensitizing agents
    Drug Categories serotonergic drugs shown to increase risk of serotonin syndrome
    (5 More Sources)

    Publications:

    Murata Y et al., 2010, Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome., J Clin Psychopharmacol
    Sugai T et al., 2006, The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine., Pharmacogenomics J
    Murphy GM Jr et al., 2003, Pharmacogenetics of antidepressant medication intolerance., Am J Psychiatry
    Wilkie MJ et al., 2009, Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy., Pharmacogenomics J
    Foster RH et al., 1997, Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder., CNS Drugs
    Meyer et al., 2001, The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study., Am J Psychiatry
    Bixo et al., 2001, Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment., Psychoneuroendocrinology
    Newcombe F et al., 1969, Alkaloids of the leaves of Voacanga schweinfurthii Stapf., Planta Med
    Tanaka M et al., 2008, Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea., Int J Neuropsychopharmacol
    Kato M et al., 2009, 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients., Psychiatry Res
    Yang Z et al., 2012, Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population., Gen Hosp Psychiatry
    Kurose K et al., 2012, Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression., Psychiatry Res
    Huang X et al., 2013, ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients., Pharmacogenomics
    Uhr M et al., 2008, Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression., Neuron
    Perroud N et al., 2011, Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample., Pharmacogenomics
    Breitenstein B et al., 2016, Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study., J Psychiatr Res
    de Klerk OL et al., 2013, ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder., Pharmacogenomics J
    Wang XC et al., 2014, Association of 2 neurotrophic factor polymorphisms with efficacy of paroxetine in patients with major depressive disorder in a Chinese population., Ther Drug Monit
    Benedetti F et al., 2009, The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting., Psychopharmacology (Berl)
    Nemeroff et al., 2003, Neuropharmacology of paroxetine., Psychopharmacol Bull
    Gilmor et al., 2002, Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine., Am J Psychiatry
    Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
    Rubin, 2000, Paroxetine binding to the rat norepinephrine transporter in vivo., Biol. Psychiatry
    Kirchheiner J et al., 2008, Genetic variants in FKBP5 affecting response to antidepressant drug treatment., Pharmacogenomics
    Zou YF et al., 2010, Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders., Neurosci Lett
    Sarginson JE et al., 2010, FKBP5 polymorphisms and antidepressant response in geriatric depression., Am J Med Genet B Neuropsychiatr Genet
    Binder EB et al., 2004, Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment., Nat Genet
    Niitsu T et al., 2013, Pharmacogenetics in major depression: a comprehensive meta-analysis., Prog Neuropsychopharmacol Biol Psychiatry
    Papiol S et al., 2007, Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment., J Affect Disord
    Hiemke C, 1994, [Paroxetine: pharmacokinetics and pharmacodynamics]., Fortschr Neurol Psychiatr
    Fujishiro J et al., 2002, Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine., Eur J Pharmacol
    Gray SL et al., 2016, Anticholinergic medication use and dementia: latest evidence and clinical implications., Ther Adv Drug Saf
    Cusack et al., 1994, Binding of antidepressants to human brain receptors: focus on newer generation compounds., Psychopharmacology (Berl.)
    Illi A et al., 2009, 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression., Neuroreport
    Drago A et al., 2008, 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies., Int J Neuropsychopharmacol
    Kato M et al., 2009, Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder., Am J Med Genet B Neuropsychiatr Genet
    Baune BT et al., 2008, Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?, Neurosci Lett
    Ishiguro S et al., 2011, Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder., Eur J Clin Pharmacol
    Yevtushenko OO et al., 2010, Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism., J Affect Disord
    Glubb DM et al., 2010, Association of a functional polymorphism in the adrenomedullin gene (ADM) with response to paroxetine., Pharmacogenomics J
    Musil R et al., 2013, No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression., Eur Arch Psychiatry Clin Neurosci
    Yoshimura R et al., 2011, The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients., Prog Neuropsychopharmacol Biol Psychiatry
    Murphy GM Jr et al., 2013, BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression., Pharmacogenet Genomics
    Domschke K et al., 2010, Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response., Int J Neuropsychopharmacol
    Wang P et al., 2018, Association of DNA methylation in BDNF with escitalopram treatment response in depressed Chinese Han patients., Eur J Clin Pharmacol
    Zou YF et al., 2010, Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients., Neuropsychobiology
    Arias B et al., 2013, TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression., Neuropsychobiology
    Lin KM et al., 2010, CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine., Pharmacogenomics
    Dobrinas M et al., 2011, Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility., Clin Pharmacol Ther
    Preuss et al., 2000, Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity., Psychiatry Res
    Wihlbäck et al., 2001, Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding., Obstet Gynecol
    Davis BA et al., 2016, Mechanism of Paroxetine (Paxil) Inhibition of the Serotonin Transporter., Sci Rep
    Scholze et al., 2000, Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter., J. Pharmacol. Exp. Ther.
    Pollock et al., 2000, Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression., Neuropsychopharmacology
    Haughey et al., 2000, The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia., J. Neurochem.
    Tsuchimine S et al., 2012, DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study., J Clin Psychopharmacol
    Thomas DR et al., 1987, Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor., Psychopharmacology (Berl)
    Westenberg HG et al., 2006, Tolerability and safety of fluvoxamine and other antidepressants., Int J Clin Pract
    Kobayashi K et al., 2012, Chronic fluoxetine selectively upregulates dopamine D₁-like receptors in the hippocampus., Neuropsychopharmacology
    Ouk K et al., 2018, Chronic paroxetine treatment prevents disruption of methamphetamine-sensitive circadian oscillator in a transgenic mouse model of Huntington's disease., Neuropharmacology
    Guo S et al., 2017, Impact of paroxetine on proximal β-adrenergic receptor signaling., Cell Signal
    Peng L et al., 2014, Fluoxetine and all other SSRIs are 5-HT2B Agonists - Importance for their Therapeutic Effects., Curr Neuropharmacol
    Zhang S et al., 2010, 5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional 'serotonin-specific reuptake inhibitors'., Neuron Glia Biol
    Hertz L et al., 2015, Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift., Front Behav Neurosci
  • PAROXETINE   FKBP5

    Interaction Score: 1.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18597649 21449676 20709156 19676097 15565110 23733030 17467808


    Sources:
    PharmGKB

  • PAROXETINE   MDGA2

    Interaction Score: 1.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22445761


    Sources:
    PharmGKB

  • PAROXETINE   REEP5

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22795047


    Sources:
    PharmGKB

  • PAROXETINE   SRP19

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22795047


    Sources:
    PharmGKB

  • PAROXETINE   P2RX4

    Interaction Score: 0.56

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction? False
    Endogenous Drug? False
    Specific Action of the Ligand Antagonist

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • PAROXETINE   TPH1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19590397 23221997 23733030


    Sources:
    PharmGKB

  • PAROXETINE   ADM

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19636336


    Sources:
    PharmGKB

  • PAROXETINE   GDNF

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24577123


    Sources:
    PharmGKB

  • PAROXETINE   HTR3B

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20075642 16534507


    Sources:
    PharmGKB

  • PAROXETINE   SLC6A4

    Interaction Score: 0.23

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name CRx-139
    Novel drug target Established target
    Trial Name paroxetine hydrochloride,Paxil, Seroxat

    PMIDs:
    10980326 11530128 27032980 10869387 23338224 9537821 11027924 10987842


    Sources:
    TEND TdgClinicalTrial DrugBank GuideToPharmacology

  • PAROXETINE   BDNF

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22965830 21338649 23733030 23619509 19236730 29748862 20016225


    Sources:
    PharmGKB

  • PAROXETINE   SLC6A2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    14566196 12359676 9537821 11203183


    Sources:
    DrugBank

  • PAROXETINE   HTR1A

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19590397 18047755 18484082 18387740 21688171 19800133 23733030


    Sources:
    PharmGKB DrugBank

  • PAROXETINE   HTR2A

    Interaction Score: 0.09

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    14514498 18253134 23338224 11136637 11403977 5821956 17697394 19361869


    Sources:
    PharmGKB DrugBank

  • PAROXETINE   COMT

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18989660


    Sources:
    PharmGKB

  • PAROXETINE   HTR2B

    Interaction Score: 0.08

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    25342944 20846463 25750618


    Sources:
    DrugBank

  • PAROXETINE   CHRM1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    7959522 12421645 27695623 7855217


    Sources:
    DrugBank

  • PAROXETINE   HTR1B

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21449676


    Sources:
    PharmGKB

  • PAROXETINE   ABCB1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24192121 18215618 21449676 26704739 22641028


    Sources:
    PharmGKB

  • PAROXETINE   DRD3

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22926616


    Sources:
    PharmGKB

  • PAROXETINE   DRD1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    other/unknown

    Interaction Info:

    PMIDs:
    23338224 22278095


    Sources:
    DrugBank

  • PAROXETINE   ADRB1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    28711716


    Sources:
    DrugBank

  • PAROXETINE   ADRA2A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    2962217


    Sources:
    DrugBank

  • PAROXETINE   DRD2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    other/unknown

    Interaction Info:

    PMIDs:
    29274752 23338224


    Sources:
    DrugBank

  • PAROXETINE   ADRA1A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    2962217


    Sources:
    DrugBank

  • PAROXETINE   HRH1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    16620364


    Sources:
    DrugBank

  • PAROXETINE   CYP3A5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PAROXETINE   MTOR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAROXETINE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21121774 21593735


    Sources:
    PharmGKB

  • PAROXETINE   ATXN2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAROXETINE   CYP2D6

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • PAROXETINE   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAROXETINE   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAROXETINE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DrugBank: DB00715

    • Version: 5.1.7

    Alternate Names:
    PAROXETINE DrugBank Drug Name
    61869-08-7 CAS Number
    Act Paroxetine Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Groups investigational

    Publications:
    Foster RH et al., 1997, Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder., CNS Drugs
    Meyer et al., 2001, The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study., Am J Psychiatry
    Bixo et al., 2001, Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment., Psychoneuroendocrinology

  • TEND: PAROXETINE

    • Version: 01-August-2011

    Alternate Names:
    PAROXETINE Primary Drug Name

    Drug Info:
    Year of Approval 1992
    Drug Class antidepressive agents, second-generation

    Publications:

  • TdgClinicalTrial: PAROXETINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antidepressant
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: paroxetine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Murata Y et al., 2010, Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome., J Clin Psychopharmacol
    Sugai T et al., 2006, The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine., Pharmacogenomics J
    Kurose K et al., 2012, Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression., Psychiatry Res

  • TTD: Paroxetine

    • Version: 2020.06.01

    Alternate Names:
    D06GDY TTD Drug ID

    Drug Info:

    Publications:

  • GuideToPharmacology: 178101492

    • Version: 29-September-2020

    Alternate Names:
    PAROXETINE GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • DTC: PAROXETINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL490 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL490

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Paroxetine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21